Cipla Signals US Launch Momentum, Commodity-Like Price Cycle

Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.